.png){kind=icon}
.png){kind=icon}
Return
Benefit from perioperative enfortumab vedotin–pembrolizumab in cisplatin-eligible MIBC
.png){kind=icon}
PRE
AI
D
DOI：10.1038/s41571-026-01195-2.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En
Journal
IF:
82.2
Papers:
2.3K
Citations:
3.3W
Organization
Cited Papers